Neurocrine Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $118.7100
- Today's High:
- $125.0000
- Open Price:
- $119.3000
- 52W Low:
- $71.88
- 52W High:
- $125
- Prev. Close:
- $119.3600
- Volume:
- 1946246
Company Statistics
- Market Cap.:
- $11.674 billion
- Book Value:
- 14.89
- Revenue TTM:
- $1.297 billion
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0.791 billion
- Gross Profit TTM:
- $0.791 billion
- Profit Margin:
- 0%
- Return on Assets TTM:
- 5.25%
- Return on Equity TTM:
- 0.9%
Company Profile
Neurocrine Biosciences Inc had its IPO on 1996-05-23 under the ticker symbol NBIX.
The company operates in the LIFE SCIENCES sector and (NO DISGNOSTIC SUBSTANCES) industry. Neurocrine Biosciences Inc has a staff strength of 0 employees.
Stock update
Shares of Neurocrine Biosciences Inc opened at $119.3 at the start of the last trading session i.e. 2022-11-02.
The stocks traded within a range of $118.71 - $125, and closed at $122.06.
This is a +2.26% increase from the previous day's closing price.
A total volume of 1,946,246 shares were traded at the close of the day’s session.
In the last one week, shares of Neurocrine Biosciences Inc have increased by +8.02%.
Neurocrine Biosciences Inc's Key Ratios
Neurocrine Biosciences Inc has a market cap of $11.674 billion, indicating a price to book ratio of 7.77 and a price to sales ratio of 8.61.
In the last 12-months Neurocrine Biosciences Inc’s revenue was $1.297 billion with a gross profit of $0.791 billion and an EBITDA of $0.179 billion. The EBITDA ratio measures Neurocrine Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Neurocrine Biosciences Inc’s operating margin was 0% while its return on assets stood at 5.25% with a return of equity of 0.9%.
In Q3, Neurocrine Biosciences Inc’s quarterly earnings growth was a negative -57.6% while revenue growth was a positive 30.9%.
Neurocrine Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 28.41
- Trailing PE
- 938.92
- PEG
- 1.87
Its diluted EPS in the last 12-months stands at $0.13 per share while it has a forward price to earnings multiple of 28.41 and a PEG multiple of 1.87. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Neurocrine Biosciences Inc’s profitability.
Neurocrine Biosciences Inc stock is trading at a EV to sales ratio of 8.23 and a EV to EBITDA ratio of 233.04. Its price to sales ratio in the trailing 12-months stood at 8.61.
Neurocrine Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $0.000 billion
- Total Liabilities
- $0.000 billion
- Operating Cash Flow
- $0.000 billion
- Capital Expenditure
- $0.000 billion
- Dividend Payout Ratio
- 0%
Neurocrine Biosciences Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.
Neurocrine Biosciences Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.
Neurocrine Biosciences Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.
In 1970, Neurocrine Biosciences Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.
Comparatively, Neurocrine Biosciences Inc paid $0 billion in dividends in 1970.
Other key metrics
- Current Trading Price
- $122.06
- 52-Week High
- $125
- 52-Week Low
- $71.88
- Analyst Target Price
- $125.08
Neurocrine Biosciences Inc stock is currently trading at $122.06 per share. It touched a 52-week high of $125 and a 52-week low of $125. Analysts tracking the stock have a 12-month average target price of $125.08.
Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Neurocrine Biosciences Inc
Similar Industry Stocks ((NO DISGNOSTIC SUBSTANCES))
Most Active
Top Gainers
Top Losers
About
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.